AKASA Prebill Optimization Suite
AKASA · Hospitals and health systems (enterprise, mid-cycle) · Cloud SaaS (remote deployment)
Revenue Cycle / Coding / Prior Auth
Generative AI suite uniting clinical documentation integrity (CDI) and medical coding in a single pre-bill workflow that reviews 100% of encounters before claims are submitted. Custom LLMs trained on each health system's own data surface documentation gaps, coding opportunities, and compliance risks to improve reimbursement accuracy and audit defensibility.
Evidence at a glance
Freshness, source-checked counts, confidence and gate results below reflect the frozen evidence snapshot through . A later editorial review does not update these results.
- Stated intended users
- CFOs, VP Revenue Cycle, and HIM/coding/CDI leaders at hospitals and health systems
- Documentary gate at snapshot
- Failed
- Scenario match
- Outside this scenario — Prior-auth automation under CMS-0057-F
- Comparability
- Not yet comparable in this scenario
- Decision readiness at snapshot
- HISTORICAL — Research only
- Documented evidence at snapshot
- 0 of 5 evidence claims source-checked · confidence Low
- Critical unknowns
- scaled production deployment · documented economic outcomes
- Latest checked-source retrieval in snapshot
- not yet measured
Expand each claim to inspect its source, dates and recorded verification status.
vendor pageAKASA states it is HITRUST-certified and SOC 2-certified, and that its platform reviews 100% of encounters pre-bill to ensure every claim re…2026-08-22
Exact claim. AKASA states it is HITRUST-certified and SOC 2-certified, and that its platform reviews 100% of encounters pre-bill to ensure every claim reflects the quality of care delivered.
- Source
- akasa.com
- Type
- vendor page
- Published
- 2026-08-22
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- trust_governance
- Score contribution
- Feeds trust governance
Self-reported by the vendor. Independent verification is pending unless marked otherwise.
Open akasa.compress releaseCleveland Clinic expanded its AKASA partnership to deploy AKASA's CDI solution across all U.S. locations, after completing an enterprise-wid…2025-10-13
Exact claim. Cleveland Clinic expanded its AKASA partnership to deploy AKASA's CDI solution across all U.S. locations, after completing an enterprise-wide rollout of AKASA's AI coding tool in four months that processes tens of thousands of encounters and 100% of the health system's inpatient volume.
- Source
- akasa.com
- Type
- press release
- Published
- 2025-10-13
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- deployment_traction
Vendor or press announcement. Verify material claims against primary filings or contracts.
Open akasa.comvendor pageAKASA blog (Aug 19, 2025) on Cleveland Clinic's mid-cycle GenAI deployment: in the first 60 days of production with the AKASA mid-cycle Opti…2025-08-19
Exact claim. AKASA blog (Aug 19, 2025) on Cleveland Clinic's mid-cycle GenAI deployment: in the first 60 days of production with the AKASA mid-cycle Optimization Suite, Cleveland Clinic experienced roughly a 50% acceptance rate for AI-flagged recommendations, higher ICD-10 capture and case mix index, and improved severity of illness, risk of mortality, and HCC capture.
- Source
- akasa.com
- Type
- vendor page
- Published
- 2025-08-19
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- economic_value
Self-reported by the vendor. Independent verification is pending unless marked otherwise.
Open akasa.compress releaseCleveland Clinic and AKASA announced a strategic collaboration to launch AI tools for the revenue cycle, with AKASA processing 100% of Cleve…2025-04-29
Exact claim. Cleveland Clinic and AKASA announced a strategic collaboration to launch AI tools for the revenue cycle, with AKASA processing 100% of Cleveland Clinic's enterprise inpatient volume.
- Source
- web.archive.org
- Type
- press release
- Published
- 2025-04-29
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v2
- Supports
- deployment_traction
Vendor or press announcement. Verify material claims against primary filings or contracts.
Open web.archive.orgindependent reportAKASA raised $120M in 2024, earning a spot on TechCrunch's list of 49 U.S. AI startups that raised $100M+ in 2024; the company reports more …2024-12-20
Exact claim. AKASA raised $120M in 2024, earning a spot on TechCrunch's list of 49 U.S. AI startups that raised $100M+ in 2024; the company reports more than $200M raised to date from investors including a16z, BOND, and Costanoa.
- Source
- techcrunch.com
- Type
- independent report
- Published
- 2024-12-20
- Retrieved
- 2026-08-27
- Verification
- unverified
- Confidence
- not stated
- Reviewer
- healthit-gate-v1
- Claim version
- v1
- Supports
- market_durability
- Score contribution
- Feeds market durability
Independent source. Methodology and sample vary by report; read the underlying method.
Open techcrunch.comVerified provider experience is not yet publishable. Fewer than five independent provider organizations have contributed eligible reviews. Reviewer mode is off. Experience never changes documentary scoring, freshness, or rank.
Buyer lenses — evidence-backed bands at snapshot (not a 0–100 rank)
Deployment, integration, data handling at snapshot
- Integration maturity
- announced — Announced or documented integration; marketplace listing not confirmed.
- EHR path
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- FHIR / API
- UNKNOWN
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- SSO
- UNKNOWN
Why unknown
Why. Single-sign-on support is not documented in vendor or marketplace materials on file.
What would close it. Vendor security documentation or marketplace listing mentioning SSO/SAML/OIDC.
- PHI / BAA
- PHI processed in-scope; HIPAA-compliant (HITRUST CSF and SOC 2 certified) · BAA available
- Security attestations
- HITRUST CSF, SOC 2
- FDA status
- UNKNOWN
Why unknown
Why. No FDA listing found for this product's functions in the tracked category.
What would close it. An FDA 510(k)/De Novo listing, or a clear statement that no regulated function is claimed.
- Pricing
- Not publicly listed
Technical provenance
snap_36bba25c577cbb44 · Evidence cutoff: 2026-08-27T04:05Z · Snapshot generated: 2026-10-21T19:39Z · build ffbf5c3
Forecast calibration is not in the public snapshot — shown as UNKNOWN rather than read from SQLite.
Known limitations
- Deployment traction is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Interoperability is UNKNOWN.
Why unknown
Why. No reliable source on file. The platform does not infer values from weak sources.
What would close it. A primary source or independent verification.
- Economic value evidence is UNKNOWN.
Why unknown
Why. No independently verifiable ROI claim (peer-reviewed, audited case, or independent benchmark) is on file.
What would close it. An audited implementation report or peer-reviewed study with payback/throughput numbers.